Last updated: May 30, 2026
Ondansetron hydrochloride preservative-free supply is dominated by manufacturers that can run sterile, preservative-free liquid fill-finish and/or sterile lyophilized presentations under cGMP. The supplier set depends on whether the product is the marketed US injectable (preservative-free) and whether you source through FDA-registered sterile facilities, CDMOs, or 503B bulk/finished-goods channels.
Which companies supply ondansetron hydrochloride preservative-free injection for US hospital and retail channels?
Featured snippet answer: Common supplier categories are (1) the FDA NDA/ANDA holders for the US marketed preservative-free product, (2) sterile contract manufacturers/CDMOs running preservative-free fill-finish, and (3) 503B outsourcing facilities that produce or repackage sterile preservative-free oncology and perioperative antiemetics for distribution.
How to map “preservative-free” correctly
- “Ondansetron hydrochloride” generics are often available in both preservative-containing and preservative-free sterile formats; many listings and procurement catalogs conflate “ondansetron injection” without flagging preservative status.
- For procurement or IP risk screening, use the exact dosage form strength and preservative-free claim from the specific label/NDC on the product you plan to procure.
What dosage forms typically exist in preservative-free sourcing
- Sterile solution, preservative-free (hospital-ready vials or ampules)
- Sterile lyophilized powder + diluent (less common in “preservative-free” labeling, but still requires preservative-free reconstitution conditions on label)
What supplier constraints narrow the vendor list
- Sterile injectable fill-finish capability with validated low-bioburden processing
- Aseptic processing qualification (media fills), particulate monitoring, and batch release testing
- Container closure system qualification for preservative-free stability (leachables/extractables)
- Ability to maintain mercantile temperature bands and chain-of-custody documentation for distributors
What suppliers produce ondansetron hydrochloride preservative-free injection sterile vials or ampules?
Featured snippet answer: Suppliers are typically either (a) the branded/ANDA manufacturers whose product is listed with an NDC for preservative-free injection or (b) CDMOs/sterile fill-finish providers that support those manufacturers’ commercial scale.
Common supply chain structure
- NDA holder or ANDA sponsor contracts with sterile fill-finish sites for final packaging in the commercial container (commonly vials).
- Distributors then list supply under that NDC. Procurement systems often require NDC-level matching.
Supplier qualification checklist (procurement-grade)
- NDC matching to the exact preservative-free label claim
- COA, sterility assurance, endotoxin limits, and batch traceability
- Stability documentation for the exact container closure
- Supply continuity history (confirmed availability, not “expected”)
Which suppliers are active in the US for ondansetron preservative-free sterile injectable manufacturing?
Featured snippet answer: Active US suppliers fall into two lanes: (1) US-licensed sterile injectable manufacturers with FDA approval for the exact preservative-free configuration, and (2) sterile CDMOs that run preservative-free aseptic fill-finish for multiple sponsors.
Lane 1: Product-name suppliers (NDC-level)
You must source at the NDC that corresponds to “preservative-free” on the label, because identical strengths can exist in both preservative-free and preservative-containing versions.
Lane 2: CDMO/sterile fill-finish
Sterile CDMOs typically do not market under the drug name; their customer list is not always public. You infer them from:
- FDA manufacturing facility listings on product records
- Establishment inspection records tied to the specific finished dosage form
- Procurement documents that identify “manufactured for” or “distributed by” relationships
How does ondansetron hydrochloride preservative-free supply compare with preservative-containing versions?
Featured snippet answer: Preservative-free versions are in demand where clinicians avoid preservative exposure for repeated dosing, neonatal or sensitive patient populations, or protocols requiring preservative-free fluids.
Practical differences affecting sourcing
- Fewer vendors can economically run preservative-free stability and aseptic release constraints
- Preservative-free vials/ampules can face more frequent shortage dynamics during capacity constraints because of narrower formulation and packaging requirements
What CDMOs or sterile manufacturers can make ondansetron hydrochloride preservative-free injection under contract?
Featured snippet answer: Contract manufacturing for preservative-free sterile injectables is limited to vendors with validated aseptic fill-finish lines that explicitly support preservative-free products.
Signals that a CDMO can support preservative-free
- Documented experience with preservative-free sterile liquids
- CMO capability statements that include aseptic processing, lyophilization, and vial/ampule filling
- Facility licensing and inspection history aligned to sterile injectable production
What outsourcing facilities (503B) supply ondansetron hydrochloride preservative-free?
Featured snippet answer: Some 503B outsourcing facilities produce sterile injectable products, including preservative-free forms, but availability is batch- and demand-dependent. In procurement workflows, you should require 503B-specific labeling compliance and lot traceability.
Where 503B sourcing fits
- When commercial supply is constrained
- For institution-specific formulary needs
- When exact dosing presentation requirements are not consistently available
What are the key regulatory and quality requirements suppliers must meet for preservative-free sterile ondansetron?
Featured snippet answer: Suppliers must meet sterility assurance, endotoxin control, cGMP aseptic processing rules, and container closure integrity expectations, with release specifications aligned to the labeled presentation.
US regulatory anchors
- cGMP for sterile drug products (aseptic processing, personnel qualification, environmental monitoring)
- USP <71> sterility testing, USP <85> bacterial endotoxins (where applicable to the finished product’s testing strategy)
- Container closure and stability expectations for preservative-free injectables
What procurement documentation should you require when sourcing ondansetron hydrochloride preservative-free?
Featured snippet answer: For preservative-free sterile injectable procurement, require NDC matching and lot-specific sterility/endotoxin COAs plus chain-of-custody and stability documentation for the specific container.
Must-have documents
- COA for sterility and endotoxin for each lot
- Spec sheet tied to the exact NDC and preservative-free label claim
- Stability statement (shelf life, in-use stability if applicable)
- Temperature excursion policy and shipping qualification details (for cold-chain or controlled room-temperature products, as labeled)
- Lot traceability and recall notification process
How many supplier options are there for ondansetron hydrochloride preservative-free, and what drives market concentration?
Featured snippet answer: The supplier pool is smaller for preservative-free sterile injectables than for preservative-containing versions because sterile fill-finish capacity, validated stability, and label configuration are narrower.
Concentration drivers
- Limited sterile fill-finish capacity for vial/ampule preservative-free sterile liquids
- Stability and formulation sensitivity for preservative-free products
- Demand surges tied to oncology cycles and perioperative schedules
- Production line downtime from aseptic processing contamination events
Key Takeaways
- Ondansetron hydrochloride preservative-free injection supply is constrained by sterile aseptic fill-finish capacity and the need to match the exact preservative-free NDC label configuration.
- Supplier identification should be done at NDC and lot level, not at “ondansetron injection” level, because preservative status varies across equivalent strengths.
- For procurement and risk control, require COAs tied to sterility and endotoxin testing, plus stability and container closure documentation for the preservative-free presentation.
FAQs
1) How do I verify that an ondansetron hydrochloride injectable is truly preservative-free?
Match the exact label claim “preservative-free” to the specific NDC and confirm on lot-specific documentation and COAs.
2) Are there both branded and generic suppliers for ondansetron hydrochloride preservative-free?
Yes, but availability depends on the specific preservative-free NDC configuration, and shortages can be presentation-specific.
3) What is the biggest risk when substituting ondansetron preservative-free with a non-preservative-free version?
Clinical protocol mismatch due to preservative exposure and product labeling differences, even when the active ingredient and strength match.
4) Can a 503B outsourcing facility supply preservative-free ondansetron consistently?
Supply can be intermittent and lot-based; institutional procurement should require NDC/label alignment and lot traceability.
5) What quality tests matter most for preservative-free sterile ondansetron injection?
Sterility assurance (sterility testing strategy) and endotoxin control, backed by lot-specific COAs and aseptic process validation records tied to the finished dosage form.
References
- U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) for Finished Pharmaceuticals and Sterile Products (guidance and regulations). FDA.
- United States Pharmacopeia. (n.d.). USP <71> Sterility Tests and USP <85> Bacterial Endotoxins Test. USP.
- U.S. Food and Drug Administration. (n.d.). Drug establishment registration and listing / facility information. FDA.
